EDAP TMS SA Reports Q4 and Full Year 2018 Results

• Record fiscal year 2018 revenues of EUR39.2 million
• Q4 2018 HIFU net sales increased 79% year-over-year
• Profitable and cash flow positive during the fourth quarter of 2018
• Completed first U.S. sale of Focal One at the end of 2018
• Ended the year with a strong cash position of $22.3 million

EDAP TMS SA EDAP, +22.33% (“the Company”), the global leader in therapeutic ultrasound, announced today financial results for the fourth quarter and full year 2018 and provided a strategic and operational update.

Marc Oczachowski, EDAP’s Chief Executive Officer, said: “We are very pleased to report our fifth consecutive year of growth during 2018, achieving total revenue of EUR39.2 million. As announced, one of the major milestones during the year was FDA clearance of Focal One in June, and just six months later, we completed the first U.S. sale of Focal One to the John Wayne Cancer Institute. We followed that up with three additional U.S. Focal One sales in less than sixty days. Our HIFU sales and marketing development teams have also been very active outside of the U.S., with the opening of new markets and further expansion in existing countries such as Brazil.

“We experienced very strong momentum during the fourth quarter in the adoption of our HIFU technology in the U.S. and internationally. Our teams are fully focused on leveraging this positive trend to further develop our sales pipeline for 2019,” Mr. Oczachowski concluded.

https://www.marketwatch.com/press-release/edap-tms-sa-edap-reports-q4-and-full-year-2018-results-2019-04-01